Recursion Pharmaceuticals (RXRX) has partnered with NVIDIA to accelerate its AI foundation models for drug discovery. The collaboration involves NVIDIA providing a $50 million investment in Recursion and offering its cloud services, NVIDIA DGX™ Cloud, for the development and distribution of AI models.
Recursion, a clinical-stage TechBio company, has been working on developing AI models to streamline drug discovery. The company has a vast proprietary dataset of biological and chemical information, which it plans to leverage with NVIDIA's computing power and AI tools. The collaboration aims to create groundbreaking foundation models in biology and chemistry that can be optimized and distributed to biotechnology companies using NVIDIA's cloud services.
This partnership is a significant milestone for Recursion, as it aligns with one of the world's leading AI companies to accelerate its mission of revolutionizing drug discovery. The collaboration involves joint research, product co-development, and the exploration of data as a value driver. Recursion will utilize NVIDIA's AI stack and full-stack computing expertise to optimize and scale its foundation models. The resulting AI tools could potentially be made available for licensing by other drug hunters via NVIDIA's BioNeMo cloud service.
The partnership between Recursion and NVIDIA is a strategic move to leverage the power of AI in drug discovery, which is a complex and time-consuming process. By combining Recursion's vast dataset with NVIDIA's computing power and AI tools, the collaboration aims to significantly speed up the drug discovery process and improve the success rate of new therapies.
